Recruiting Lymphoma Studies in Minneapolis
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
Background: Lymphoma is a type of blood cancer. Blood cell transplant can cure some people with lymphoma. Researchers want to see if they can limit the complications transplant can cause. Objective:...
A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.
The purpose of this study is to learn about the effects of two study medicines (maplirpacept \[PF-07901801\] and glofitamab) when given together for the treatment of diffuse large B-cell lymphoma (DLB...
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma
The purpose of this study is to assess the safety, tolerability, drug levels, and preliminary efficacy of relatlimab plus nivolumab in pediatric and young adult participants with recurrent or refracto...
Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
This is a Phase I/II, multicenter, open-label, dose escalation/dose-expansion study to evaluate the tolerability, safety, and the maximum tolerated dose (MTD) of ruxolitinib when given with fixed dose...
Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma
This phase II trial investigates how well modified VR-CAP (bortezomib, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, and cytarabine hydrochloride) and acalabrutinib as first line...
Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
This phase Ib/II trial evaluates the safety, optimal dose, and efficacy of the combination of epcoritamab and ibrutinib in treating patients with aggressive B-cell non-Hodgkin lymphoma that has come b...
About Lymphoma Clinical Trials in Minneapolis
Lymphoma is a cancer of the lymphatic system that affects infection-fighting cells called lymphocytes. The two main types are Hodgkin lymphoma and non-Hodgkin lymphoma. Treatment often includes chemotherapy, radiation, immunotherapy, and in some cases stem cell transplant.
There are currently 6 lymphoma clinical trials recruiting participants in Minneapolis, MINNESOTA. These studies are seeking a combined 605 participants. Research is being sponsored by National Cancer Institute (NCI), Pfizer, Bristol-Myers Squibb and 3 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Lymphoma Clinical Trials in Minneapolis — FAQ
Are there lymphoma clinical trials in Minneapolis?
Yes, there are 6 lymphoma clinical trials currently recruiting in Minneapolis, MINNESOTA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Minneapolis?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Minneapolis research site will contact you about next steps.
Are clinical trials in Minneapolis free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Minneapolis studies also compensate for your time and travel.
What lymphoma treatments are being tested?
The 6 active trials in Minneapolis are testing new therapies including novel drugs, biologics, and treatment approaches for lymphoma.
Data updated March 2, 2026 from ClinicalTrials.gov